Source:http://linkedlifedata.com/resource/pubmed/id/17495423
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2007-7-20
|
| pubmed:abstractText |
The objective of the present study was to investigate the effects of octreotide long acting release (S-LAR) preparation on GH and IGF-1 serum concentrations and pituitary tumor size in patients with persistent and difficultly controlled acromegaly even after adjuvant irradiation and/or dopamine agonists. Thirty-three patients with active acromegaly (26 female and 7 male, mean age; 43.94 +/- 14.01 SD years) were included in this study. Patients were evaluated at baseline and at 6, 12, 30 and 40 months for GH, IGF-1, and GH response to OGTT and biliary ultrasonography. Sella MRI was performed at initial and at 40 months. All patients received 20 mg S-LAR. Afterwards, the dosage was titrated to improve individual GH response and reduction of IGF-1 into normal ranges. Basal serum IGF-1 levels decreased from median: 530 microg/l [IQR: 420-600] to 340 microg/l [IQR: 230-460] at 6 months (p = 0.01), to 400 microg/l [IQR: 222.4-600] at 12 months (p = 0.48), to 396 microg/l [IQR: 318-468] at 30 months (p = 0.49), to 482 microg/l [308-580] at 40 months (p = 0.47). Nadir GH levels in OGTT fell from 2.70 ng/ml [IQR: 1.35-6.90] to 1.60 ng/ml [IQR: 0.36-4.10] at 6 months (p = 0.03), to 0.31 ng/ml [IQR: 0.18-0.65] at 12 months (p<0.0001), to 1.50 ng/ml [IQR: 0.83-4.00] at 30 months (p = 0.398) and to 0.89 ng/ml [IQR: 0.58-1.35] at 40 months (p<0.0001). Initially, pituitary adenoma volume was median: 1.18 ml [IQR: 0.08-3.50] and it shrank to 0.21 ml [IQR: 0-2.1] at 40 months (p = 0.08). Gallstones were detected in 12 patients and six of them underwent cholecystectomy. S-LAR is an effective treatment regimen in reducing GH and IGF-1 concentrations and as well as in shrinking tumor volume in persistent and difficultly controlled acromegalic patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Delayed-Action Preparations,
http://linkedlifedata.com/resource/pubmed/chemical/Human Growth Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I,
http://linkedlifedata.com/resource/pubmed/chemical/Octreotide,
http://linkedlifedata.com/resource/pubmed/chemical/Somatostatin
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0918-8959
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
54
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
459-64
|
| pubmed:meshHeading |
pubmed-meshheading:17495423-Acromegaly,
pubmed-meshheading:17495423-Adenoma,
pubmed-meshheading:17495423-Adult,
pubmed-meshheading:17495423-Comorbidity,
pubmed-meshheading:17495423-Delayed-Action Preparations,
pubmed-meshheading:17495423-Dose-Response Relationship, Drug,
pubmed-meshheading:17495423-Female,
pubmed-meshheading:17495423-Follow-Up Studies,
pubmed-meshheading:17495423-Glucose Tolerance Test,
pubmed-meshheading:17495423-Growth Hormone-Secreting Pituitary Adenoma,
pubmed-meshheading:17495423-Human Growth Hormone,
pubmed-meshheading:17495423-Humans,
pubmed-meshheading:17495423-Insulin-Like Growth Factor I,
pubmed-meshheading:17495423-Male,
pubmed-meshheading:17495423-Middle Aged,
pubmed-meshheading:17495423-Neoplasm, Residual,
pubmed-meshheading:17495423-Octreotide,
pubmed-meshheading:17495423-Salvage Therapy,
pubmed-meshheading:17495423-Somatostatin,
pubmed-meshheading:17495423-Treatment Failure
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide.
|
| pubmed:affiliation |
Division of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Turkey.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|